Boston Scientific Corporation (BSX) Price Target Analysis
Wall Street analyst price targets, ratings consensus & upside potential · Updated May 1, 2026
Current Price
$56.00
Price Target
$91.33
Target Range
$60.00 — $120.00
Analyst Rating
Buy
Forward P/E16.6x
Trailing P/E28.9x
Forward PEG—
Implied Growth+74.8%
Median Target$90.00
Analyst Spread65.7%
Price Forecast (1 Year)
Last 12 months price action with 12-month analyst target path
Bear Case
$60
+7.1%
Consensus
$91
+63.1%
Bull Case
$120
+114.3%
Valuation Model TargetsConfidence: 74/100
Bear$17
Base$92
Bull$72
BSX Price Target Analysis
Updated May 7, 2026As of May 7, 2026, Boston Scientific Corporation (BSX) has a Wall Street consensus price target of $91.33, based on estimates from 43 covering analysts. With the stock currently trading at $56.00, this represents a potential upside of +63.1%. The company has a market capitalization of $83.23B.
Analyst price targets range from a low of $60.00 to a high of $120.00, representing a 66% spread in expectations. The median target of $90.00 aligns closely with the consensus average. The wide target spread reflects significant disagreement on fair value.
The current analyst consensus rating is Buy, with 40 analysts rating the stock as a Buy or Strong Buy,3 rating it Hold, and 0 rating it Sell or Strong Sell. This overwhelmingly bullish sentiment suggests analysts see significant catalysts for upside ahead.
From a valuation perspective, BSX trades at a trailing P/E of 28.9x and forward P/E of 16.6x. Analysts expect EPS to grow +74.8% over the next year.
Our proprietary valuation model, which blends historical multiples with forward estimates, suggests a base-case price target of $91.77, with bear and bull scenarios of $17.49 and $71.56 respectively. Model confidence stands at 74/100, indicating high predictability in the company's fundamentals.
Investment Context: Price targets represent analyst expectations for the next 12 months and should be considered alongside your own research. Targets are based on analysts' assumptions about earnings growth, margins, and market conditions which may change. For sector-specific context, view other Healthcare stocks.
Analyst Sentiment Comparison
Industry Peer AnalysisAvg Peer Upside+34.3%
Avg Forward P/E18.7x
Peers with Coverage10 / 10
| Company | Market Cap | Price | Target | Upside | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
 MDTMedtronic plc | $99.5B | $77.60 | $109.50 | +41.1% | Buy | 14.1x | 49 |
 EWEdwards Lifesciences Corporation | $48.0B | $83.20 | $96.53 | +16.0% | Buy | 27.7x | 48 |
 SYKStryker Corporation | $112.0B | $292.33 | $403.69 | +38.1% | Buy | 19.5x | 50 |
 ZBHZimmer Biomet Holdings, Inc. | $16.2B | $82.83 | $97.90 | +18.2% | Hold | 9.8x | 42 |
 BDXBecton, Dickinson and Company | $52.4B | $144.76 | $172.85 | +19.4% | Buy | 11.6x | 33 |
 BAXBaxter International Inc. | $8.8B | $16.98 | $19.75 | +16.3% | Hold | 8.9x | 36 |
 HOLXHologic, Inc. | $17.0B | $76.01 | $79.00 | +3.9% | Hold | 17.2x | 42 |
 ABTAbbott Laboratories | $150.0B | $86.25 | $128.71 | +49.2% | Buy | 15.7x | 41 |
 ISRGIntuitive Surgical, Inc. | $160.4B | $451.73 | $622.60 | +37.8% | Buy | 43.7x | 55 |
 NVCRNovoCure Limited | $1.9B | $16.50 | $33.50 | +103.1% | Buy | — | 15 |
Upside Potential Comparison
NVCRABTMDTSYKISRGBDXZBHBAXFull BSX Stock Analysis
Analyst consensus, bull case, AI-generated risk factors, and peer comparison — all in one place.
See BSX's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs BSX Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare BSX vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonBSX — Frequently Asked Questions
Quick answers to the most common questions about buying BSX stock.
What is the BSX stock price target for 2026?
The consensus Wall Street price target for BSX is $91.33, representing 63.1% upside from the current price of $56. With 43 analysts covering the stock, this strong upside suggests significant value not yet reflected in today's share price.
Is BSX a buy, sell, or hold?
BSX has a consensus rating of "Buy" based on 43 Wall Street analysts. The rating breakdown is predominantly bullish, with 40 Buy/Strong Buy ratings. The consensus 12-month price target of $91.33 implies 63.1% upside from current levels.
Is BSX stock overvalued or undervalued?
With a forward P/E of 16.5793x, BSX trades at a relatively low valuation. The consensus target of $91.33 implies 63.1% appreciation, suggesting meaningful undervaluation.
How high can BSX stock go?
The most bullish Wall Street analyst has a price target of $120 for BSX, while the most conservative target is $60. The consensus of $91.33 represents the median expectation. Our quantitative valuation model projects a bull case target of $72 based on optimistic growth and margin assumptions. These targets typically reflect 12-month expectations.
How many analysts cover BSX stock?
BSX is heavily covered by Wall Street, with 43 analysts providing price targets and ratings. Of these, 1 have Strong Buy ratings, 39 have Buy ratings, 3 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
What is the BSX stock forecast?
The 12-month BSX stock forecast based on 43 Wall Street analysts shows a consensus price target of $91.33, with estimates ranging from $60 (bear case) to $120 (bull case). The median consensus rating is "Buy". Our proprietary valuation model produces a base case fair value of $92, with bear/bull scenarios of $17/$72.
What is BSX's fair value based on fundamentals?
Our quantitative valuation model calculates BSX's fair value at $92 (base case), with a bear case of $17 and bull case of $72. The model uses discounted cash flow analysis, historical growth rates, and margin mean-reversion to project FY+2 earnings, then applies an appropriate P/E multiple. The model confidence score is 74/100.
What is BSX's forward P/E ratio?
BSX trades at a forward P/E ratio of 16.6x based on next-twelve-months earnings estimates compared to a trailing P/E of 28.9x. The lower forward P/E indicates analysts expect earnings growth. A forward P/E is useful for comparing valuations when earnings are expected to change significantly.
Should I buy BSX stock?
Wall Street analysts are very optimistic on BSX, with a "Buy" consensus rating and $91.33 price target (63.1% upside). 40 of 43 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
Why do BSX price targets vary so much?
BSX analyst price targets range from $60 to $120, a 66% wide spread indicating significant analyst disagreement. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $91.33 consensus represents the middle ground. Our model's $17-$72 range provides an independent fundamental perspective.